Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine in Comparison With an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine Containing the Alternate B Strain, in Adults Aged 65 Years and Above
Conditions
Interventions
MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)
Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1)
+1 more
Locations
20
United States
Coastal Clinical Research, Inc.
Mobile, Alabama, United States
Anaheim Clinical Trials
Anaheim, California, United States
Paradigm clinical Research Centers, Inc
Redding, California, United States
Clinical Research of South Florida, an AMR Company
Coral Gables, Florida, United States
Meridan Clinical Research, LLC
Savannah, Georgia, United States
Advanced Clinical Research
Meridian, Idaho, United States
Start Date
October 17, 2017
Primary Completion Date
December 11, 2017
Completion Date
May 17, 2018
Last Updated
July 22, 2020
NCT06355232
NCT06622590
NCT05227001
NCT05446740
NCT06602531
NCT05823974
Lead Sponsor
Seqirus
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions